RaQualia Pharma Inc. announced consolidated earnings results for the nine months ended September 30, 2018. For the period, net sales of JPY 532 million compared to JPY 606 million a year ago. Operating loss was JPY 835 million compared to JPY 554 million a year ago. Ordinary loss was JPY 818 million compared to JPY 487 million a year ago. Loss attributable to owners of the parent was JPY 844 million compared to JPY 463 million a year ago. Earnings per basic share were JPY 41.47 compared to JPY 24.16 a year ago.

For the fiscal year ending December 31, 2018, on consolidated basis, the company expects net sales of JPY 1,028 million, operating loss of JPY 1,018 million, ordinary loss of JPY 996 million, loss attributable to owners of parent of JPY 1,024 million and loss per basic share of JPY 50.31.